secwatch.observer — SEC 8-K summary
======================================

Issuer:     HALOZYME THERAPEUTICS, INC. (HALO)
CIK:        0001159036
Form:       8-K
Filed at:   2025-11-12T23:59:59+00:00
Accession:  0001193125-25-277988
Event type: debt
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 2.03, 3.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Halozyme issues $1.5B in convertible notes; repurchases $1.02B of existing notes
--------------------------------------------------------------------------------

- Issued $750M 0% convertible notes due 2031 and $750M 0.875% notes due 2032; net proceeds ~$1.47B.
- Used ~$1.02B to repurchase 0.25% notes due 2027 and 1.00% notes due 2028 via private transactions.
- Entered capped call transactions ($182.7M) to limit dilution; cap price $136.78 vs conversion price $87.20.
- Remaining proceeds for general corporate purposes, potential acquisitions, and future note repurchases.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1159036/000119312525277988/0001193125-25-277988-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1159036/000119312525277988/d945920d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-277988

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer